Haemovigilance: Are there significant differences among plasma products?

Transfusion and Apheresis Science

Volumn 43, Issue 3, 2010, Pages 407-409

  Mayr, Wolfgang R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; BLOOD CLOTTING FACTOR; DETERGENT; FRESH FROZEN PLASMA; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HNA ANTIBODY; HUMAN NEUTROPHIL ANTIGEN 1A; HUMAN NEUTROPHIL ANTIGEN 2A; HUMAN NEUTROPHIL ANTIGEN 3A; IMMUNOGLOBULIN A ANTIBODY; PLASMA SUBSTITUTE; SOLVENT; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BLOOD COMPATIBILITY; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE; PEANUT ALLERGY; POSTTRANSFUSION THROMBOCYTOPENIA; THROMBOCYTOPENIA; TRANSFUSION RELATED ACUTE LUNG INJURY;

BLOOD SAFETY; DETERGENTS; HUMANS; PLASMA; PLASMA EXCHANGE; SOLVENTS;

EID: 78649472128     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.09.004     Document Type: Article

References (19)

1. Guide to the Preparation, Use and Quality Assurance of Blood Components. 15th ed. Strasbourg: Council of Europe Publishing; 2010.
2. Contreras M., Ala F.A., Greaves M., Jones J., Levin M., Machin S.J., et al. Guidelines for the use of fresh frozen plasma. British committee for standards in haematology, working party of the blood transfusion task force. Transfus Med 1992, 2:57-63.
3. Hellstern P. Fresh-frozen plasma pathogen-reduced single-donor plasma or bio-pharmaceutical plasma. Transfus Apher Sci 2008, 39:69-74.
4. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39:75-82.
5. Solheim B.G., Seghatchian J. The six questions of pathogen reduction technology: an overview of current opinions. Transfus Apher Sci 2008, 39:51-57.
6. Reil A., Keller-Stanislawski B., Günay S., Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sanguinis 2008, 95:313-317.
7. Keller-Stanislawski B., Reil A., Günay S., Funk M.B. Frequency and severity of transfusion-related acute lung injury - German haemovigilance data (2006-2007). Vox Sanguinis 2010, 98:70-77.
8. Rapport annuel - Hemovigilance 2007. http://www.afssaps.fr/var/afssaps_site/storage/original/application/e92822f8ff7cb27d5f2009c9ac27bf1c.pdf.
9. Rapport annuel - Hemovigilance 2008. http://www.afssaps.fr/var/afssaps_site/storage/original/application/8cd23a5cc28ff824c5ea95e1974b6b19.pdf.
10. Jutzi M., Levy G., Mansouri Taleghani B. Swiss haemovigilance data and implementation of measures for the prevention of transfusion associated acute lung injury (TRALI). Transfus Med Hemother 2008, 35:98-101.
11. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2009. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm204763.htm.
12. Sinnott P., Bodger S., Gupta A., Brophy M. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet 2004, 31:271-274.
13. Eder A.F., Dy B.A., Herron R.M., Strupp A., Dodd R.Y. Effective reduction of TRALI risk with plasma collected predominantly from male donors. Transfusion 2009, 49(Suppl.):45A.
14. Pavenski K., Webert K.E., Goldman M. Consequences of transfusion of platelet antibody: a case report, literature review. Transfusion 2008, 48:1981-1989.
15. Arnold D.M., Blajchman M.A., DiTomasso J., Kulczycki M., Keith P.K. Passive transfer of peanut hypersensitivity by fresh frozen plasma. Arch Intern Med 2007, 167:853-854.
16. Wieding J.U., Vehmeyer K., Dittman J., Hiddemann W., Köhler M., Lanzer G. Contamination of fresh-frozen plasma with viable white cells and proliferable stem cells. Transfusion 1994, 34:185-186.
17. Hellstern P., Sachse H., Schwinn H., Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sanguinis 1992, 63:178-185.
18. Heger A., Svae T.E., Neisser-Svae A., Jordan S., Behizad M., Römisch J. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG™ after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sanguinis 2009, 97:219-225.
19. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 2007, 33(Suppl. 1):17-21.